AbbVie Inc. $ABBV Shares Sold by Sigma Planning Corp

Sigma Planning Corp trimmed its holdings in AbbVie Inc. (NYSE:ABBV) by 42.1% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 58,921 shares of the company’s stock after selling 42,829 shares during the period. Sigma Planning Corp’s holdings in AbbVie were worth $13,643,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of ABBV. Alliance Wealth Advisors LLC UT raised its stake in shares of AbbVie by 5.8% during the 3rd quarter. Alliance Wealth Advisors LLC UT now owns 20,463 shares of the company’s stock worth $4,738,000 after buying an additional 1,122 shares in the last quarter. Lansforsakringar Fondforvaltning AB publ boosted its stake in shares of AbbVie by 2.6% in the third quarter. Lansforsakringar Fondforvaltning AB publ now owns 556,498 shares of the company’s stock valued at $128,852,000 after buying an additional 14,162 shares in the last quarter. Intrust Bank NA grew its holdings in AbbVie by 2.2% during the third quarter. Intrust Bank NA now owns 25,437 shares of the company’s stock worth $5,890,000 after acquiring an additional 554 shares during the period. Cannon Wealth Management Services LLC purchased a new position in AbbVie in the third quarter worth $214,000. Finally, Journey Advisory Group LLC raised its position in AbbVie by 2.0% in the third quarter. Journey Advisory Group LLC now owns 50,285 shares of the company’s stock worth $11,643,000 after acquiring an additional 1,010 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: FDA approved the VENCLEXTA® (venetoclax) + acalabrutinib combination for previously untreated chronic lymphocytic leukemia (CLL). This is the first all‑oral, fixed‑duration combo for this setting, supported by Phase 3 AMPLIFY data—it can meaningfully expand uptake for Venclexta and acalabrutinib, strengthen AbbVie’s oncology franchise and offer a durable revenue stream versus one‑off treatments. U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
• Positive Sentiment: Industry write‑ups frame the FDA approval as a potential new standard for a slow‑growing blood cancer, highlighting better three‑year outcomes and the “time off therapy” selling point—this can accelerate physician adoption and market share vs. chemo regimens. FDA Approval For AbbVie/AstraZeneca’s Combination Treatment Could Set New Standard For Slow Growing Blood Cancer
• Positive Sentiment: AbbVie opened a Phase 2a study for ABBV‑142 in idiopathic pulmonary fibrosis (IPF), broadening its respiratory/pulmonary pipeline beyond core immunology and oncology programs. Early‑stage pipeline depth helps investor sentiment around post‑Humira growth optionality. AbbVie Expands IPF Pipeline With New Phase 2a Study of ABBV-142
• Positive Sentiment: Board declared a $1.73 quarterly dividend (yield ~3.1%), reinforcing the income profile for dividend‑focused investors and supporting the stock’s defensive appeal. Dividend cadence and yield matter for total return expectations. AbbVie Declares Quarterly Dividend
• Neutral Sentiment: Quarterly results and commentary show Rinvoq and Skyrizi continuing to drive top‑line growth and offset Humira erosion; that underpins management’s guidance but much of these dynamics are already reflected in recent estimates. Will Immunology Drugs Continue to Drive AbbVie’s Top Line in 2026?
• Neutral Sentiment: Coverage pieces ask whether AbbVie’s post‑Humira pipeline merits renewed investor attention — useful for narrative, but these are discussion pieces rather than new data that would immediately re‑rate the stock. Should AbbVie’s (ABBV) Post-Humira Pipeline Progress Prompt a Fresh Look From Investors?
• Neutral Sentiment: Marketing/PR items (new podcast, inclusion in dividend lists, media mentions) help brand and investor awareness but are unlikely to move fundamentals in the near term. AbbVie heads to ‘The Persistence Lab’ in new podcast highlighting healthcare innovation
• Negative Sentiment: Evercore noted Tremfya’s share gains but flagged possible limits to future earnings growth and trimmed its price target slightly—this is a modest analyst headwind that could cap upside if more firms follow with tepid updates. Evercore Notes AbbVie Inc.’s (ABBV) Tremfya Gains Market Share, But Future Earnings Growth May Be Limited

Wall Street Analysts Forecast Growth

Several brokerages have commented on ABBV. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. JPMorgan Chase & Co. raised their price objective on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. UBS Group dropped their target price on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a report on Thursday, February 5th. Finally, Barclays began coverage on shares of AbbVie in a research report on Thursday. They set an “overweight” rating and a $275.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and a consensus price target of $252.79.

AbbVie Price Performance

Shares of ABBV opened at $224.94 on Friday. The firm has a 50 day simple moving average of $224.04 and a 200-day simple moving average of $222.06. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81. The stock has a market cap of $397.56 billion, a price-to-earnings ratio of 95.31, a price-to-earnings-growth ratio of 0.78 and a beta of 0.35.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.AbbVie’s revenue was up 10.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio is currently 293.22%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.